ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) announced today that a second compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will proceed into preclinical development. In June it was announced that the first AMRI compound resulting from this collaboration was to undergo Phase I studies in Canada.
